ORIGINAL RESEARCH article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
This article is part of the Research TopicDeciphering molecular mechanisms behind tumor heterogeneity features by using nucleic acid-based technologiesView all 6 articles
Differentially Expressed Proteins in Plasma-Derived Extracellular Vesicles from Chronic Myeloid Leukemia Patients
Provisionally accepted
Denise Kusma Wosniaki1
Alexandre Luiz Korte de Azevedo2
Anelis Marin1
Alexis Germán Murillo Carrasco3
Luciana N S Andrade3
Rodrigo Brant1Michel Batista1Talita Helen Bombardelli Gomig2
Roger Chammas3
Mateus Aoki1
Dalila Lucíola Zanette1,4*- 1Instituto Carlos Chagas, Curitiba, Brazil
- 2Universidade Federal do Parana, Curitiba, Brazil
- 3Universidade de Sao Paulo, São Paulo, Brazil
- 4Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic myeloid leukemia (CML) is driven by the BCR::ABL1 fusion gene. Although tyrosine kinase inhibitors (TKIs) have transformed outcomes, treatment resistance persists. Plasma extracellular vesicles (EVs) reflect their cell of origin and may serve as stable biomarkers. To characterize the plasma EV proteome in CML patients with distinct treatment responses and T315I mutation status. EVs were isolated from the plasma of healthy controls (HC) and CML patients classified as good (GTR) or poor (PTR) treatment responders, treatment-free remission (TFR), and T315I or pre-T315I mutation carriers. EVs were purified by size-exclusion chromatography, characterized by NTA and TEM, and analyzed by label-free mass spectrometry, followed by differential expression, enrichment, and protein–protein interaction analyses. A total of 598 proteins were identified, 257 retained after quality and abundance filtering. Forty-two proteins were differentially expressed among HC, GTR, and PTR groups (p < 0.01), with PTR samples showing marked downregulation of cytoskeletal and chaperone proteins (such as MYH9, HSP90AB1, FERMT3). TFR patients exhibited distinct enrichment in complement and coagulation cascades (C3, C4B, F9, F11) and metabolic pathways. Plasma EV proteomes reflect CML clinical status, revealing immune and cytoskeletal alterations associated with treatment response, remission, and resistance, suggesting potential biomarkers for disease monitoring.
Keywords: biomarkers, Chronic myeloid leukemia, extracellular vesicles, Proteomics, T315I
Received: 06 Dec 2025; Accepted: 23 Jan 2026.
Copyright: © 2026 Kusma Wosniaki, Korte de Azevedo, Marin, Murillo Carrasco, Andrade, Brant, Batista, Bombardelli Gomig, Chammas, Aoki and Zanette. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dalila Lucíola Zanette
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.